Acutus Medical (AFIB)
(Delayed Data from OTC)
$0.04 USD
+0.01 (18.10%)
Updated Sep 11, 2024 11:33 AM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
AFIB 0.04 +0.01(18.10%)
Will AFIB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AFIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AFIB
Acutus Medical, Inc. (AFIB) Reports Q2 Loss, Tops Revenue Estimates
USANA Health Sciences (USNA) Tops Q2 Earnings and Revenue Estimates
AFIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acutus Medical, Inc. (AFIB) Q4 Earnings and Revenues Surpass Estimates
Acutus Medical, Inc. (AFIB) Reports Q3 Loss, Tops Revenue Estimates
Lyell Immunopharma (LYEL) Reports Q3 Loss, Lags Revenue Estimates
Other News for AFIB
AFIB Stock Earnings: Acutus Medical Reported Results for Q2 2024
Acutus Medical GAAP EPS of -$0.03, revenue of $4.12M
Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results